Self-assembling of individual molecular building blocks—small-molecule prodrugs—promises to facilitate the construction of nanodrugs without the requirement of adjuvant materials. Unfortunately, rationally designing systemically injectable nanoassemblies for those highly hydrophobic chemotherapeutics still represents a great challenge in cancer drug development.